|
KR20190007106A
(ko)
|
2011-12-21 |
2019-01-21 |
노비라 테라퓨틱스, 인코포레이티드 |
B형 간염의 항바이러스성 제제
|
|
KR102271574B1
(ko)
|
2012-08-28 |
2021-07-01 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도
|
|
SI2961732T1
(sl)
|
2013-02-28 |
2017-07-31 |
Janssen Sciences Ireland Uc |
Sulfamoil-arilamidi in njihova uporaba kot zdravila za zdravljenje hepatitisa B
|
|
PT2981536T
(pt)
|
2013-04-03 |
2017-08-09 |
Janssen Sciences Ireland Uc |
Derivados de n-fenil-carboxamida e sua utilização como medicamentos para o tratamento da hepatite b
|
|
JO3603B1
(ar)
|
2013-05-17 |
2020-07-05 |
Janssen Sciences Ireland Uc |
مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
|
|
US10160743B2
(en)
|
2013-05-17 |
2018-12-25 |
Janssen Sciences Ireland Uc |
Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
|
SG11201600522UA
(en)
|
2013-07-25 |
2016-02-26 |
Janssen Sciences Ireland Uc |
Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
|
NZ717629A
(en)
|
2013-10-23 |
2021-12-24 |
Janssen Sciences Ireland Uc |
Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
|
US10392349B2
(en)
|
2014-01-16 |
2019-08-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
KR20160128305A
(ko)
|
2014-02-05 |
2016-11-07 |
노비라 테라퓨틱스, 인코포레이티드 |
Hbv 감염의 치료를 위한 병용 요법
|
|
CN110483484A
(zh)
|
2014-02-06 |
2019-11-22 |
爱尔兰詹森科学公司 |
氨磺酰基吡咯酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
|
|
AU2015367509B2
(en)
|
2014-12-18 |
2020-01-02 |
F. Hoffmann-La Roche Ag |
Tetrahydro-pyrido(3,4-b)indole estrogen receptor modulators and uses thereof
|
|
WO2016146591A1
(en)
*
|
2015-03-16 |
2016-09-22 |
Astrazeneca Ab |
Combination treatment
|
|
EA201792069A1
(ru)
|
2015-03-19 |
2018-04-30 |
Новира Терапьютикс, Инк. |
Производные азокана и азонана и способы лечения инфекций гепатита в
|
|
CN107406457B
(zh)
*
|
2015-06-16 |
2019-02-01 |
江苏恒瑞医药股份有限公司 |
哌啶类衍生物、其制备方法及其在医药上的应用
|
|
US10875876B2
(en)
|
2015-07-02 |
2020-12-29 |
Janssen Sciences Ireland Uc |
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
|
WO2017024318A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
HK1259410A1
(zh)
|
2015-09-29 |
2019-11-29 |
诺维拉治疗公司 |
乙型肝炎抗病毒剂的晶体形式
|
|
CN113248494A
(zh)
|
2015-10-01 |
2021-08-13 |
奥列马制药公司 |
四氢-1H-吡啶[3,4-b]吲哚类抗雌激素药物
|
|
CN107428758B
(zh)
*
|
2015-11-12 |
2020-08-04 |
浙江海正药业股份有限公司 |
丙烯酸类衍生物、其制备方法及其在医药上的用途
|
|
RU2747802C2
(ru)
|
2015-12-09 |
2021-05-14 |
Зе Боард Оф Трастис Оф Зе Юниверсити Оф Иллинойс |
Бензотиофеновые селективные блокаторы эстрогеновых рецепторов
|
|
HK1244808A1
(zh)
|
2015-12-22 |
2018-08-17 |
江苏恒瑞医药股份有限公司 |
苯并哌啶类衍生物、其制备方法及其在医药上的应用
|
|
AU2017213614B2
(en)
*
|
2016-02-05 |
2022-09-01 |
Inventisbio Llc |
Selective estrogen receptor degraders and uses thereof
|
|
RU2738646C2
(ru)
*
|
2016-04-01 |
2020-12-15 |
РЕКЬЮРИУМ АйПи ХОЛДИНГС, ЛЛС |
Модуляторы эстрогеновых рецепторов
|
|
CA3021068A1
(en)
|
2016-04-15 |
2017-10-19 |
Novira Therapeutics, Inc. |
Combinations and methods comprising a capsid assembly inhibitor
|
|
WO2017182493A1
(en)
|
2016-04-20 |
2017-10-26 |
Astrazeneca Ab |
Indazole derivatives for use in down-regulation of the estrogen receptor for the treatment of cancer
|
|
PL3449017T3
(pl)
|
2016-04-29 |
2022-06-27 |
Board Of Regents, The University Of Texas System |
Ukierunkowane pomiary aktywności transkrypcyjnej związanej z receptorami hormonów
|
|
CN109661393A
(zh)
*
|
2016-05-08 |
2019-04-19 |
上海诚妙医药科技有限公司 |
帕布昔利布的新晶型及其制备方法及其用途
|
|
WO2017197046A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
C3-carbon linked glutarimide degronimers for target protein degradation
|
|
WO2017197055A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
EP3455219A4
(en)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
|
|
EP3454862B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
CN109311876B
(zh)
*
|
2016-06-16 |
2022-05-03 |
豪夫迈·罗氏有限公司 |
杂芳基雌激素受体调节剂及其用途
|
|
US20170362228A1
(en)
|
2016-06-16 |
2017-12-21 |
Genentech, Inc. |
TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
|
|
WO2018001232A1
(zh)
*
|
2016-06-29 |
2018-01-04 |
浙江海正药业股份有限公司 |
丙烯酸类衍生物及其制备方法和其在医药上的用途
|
|
MX2019000200A
(es)
|
2016-07-01 |
2019-09-26 |
G1 Therapeutics Inc |
Agentes antiproliferativos basados en pirimidina.
|
|
WO2018019793A1
(en)
|
2016-07-25 |
2018-02-01 |
Astrazeneca Ab |
N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer
|
|
CN107814798B
(zh)
*
|
2016-09-14 |
2020-11-03 |
四川科伦博泰生物医药股份有限公司 |
3-取代丙烯酸类化合物及其制备方法和用途
|
|
WO2018065501A1
(en)
|
2016-10-05 |
2018-04-12 |
F. Hoffmann-La Roche Ag |
Methods for preparing antibody drug conjugates
|
|
WO2018081168A2
(en)
|
2016-10-24 |
2018-05-03 |
The Board Of Trustees Of The University Of Illinois |
Benzothiophene-based selective mixed estrogen receptor downregulators
|
|
EP3433256B1
(en)
|
2016-10-24 |
2019-08-07 |
Astrazeneca AB |
6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivative useful in the treatment of cancer
|
|
EA201991622A1
(ru)
|
2017-01-06 |
2020-01-23 |
Г1 Терапьютикс, Инк. |
Комплексная терапия для лечения рака
|
|
WO2018130124A1
(zh)
*
|
2017-01-11 |
2018-07-19 |
南京圣和药业股份有限公司 |
作为选择性雌激素受体下调剂的三环类化合物及其应用
|
|
WO2018130123A1
(zh)
*
|
2017-01-11 |
2018-07-19 |
南京圣和药业股份有限公司 |
作为选择性雌激素受体下调剂的五环类化合物及其应用
|
|
CR20190379A
(es)
*
|
2017-01-30 |
2019-10-21 |
Astrazeneca Ab |
Moduladores del receptor de estrógeno
|
|
EP4119552A1
(en)
|
2017-02-08 |
2023-01-18 |
Dana-Farber Cancer Institute, Inc. |
Regulating chimeric antigen receptors
|
|
EP3580223A4
(en)
|
2017-02-10 |
2021-01-06 |
G1 Therapeutics, Inc. |
Benzothiophene estrogen receptor modulators
|
|
CN108864080B
(zh)
*
|
2017-05-09 |
2021-10-15 |
南京圣和药业股份有限公司 |
作为选择性雌激素受体下调剂的四环类化合物及其应用
|
|
CN110769822A
(zh)
|
2017-06-20 |
2020-02-07 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
|
WO2018233591A1
(zh)
*
|
2017-06-20 |
2018-12-27 |
江苏恒瑞医药股份有限公司 |
一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法
|
|
KR102659211B1
(ko)
|
2017-06-29 |
2024-04-18 |
쥐원 쎄라퓨틱스, 인크. |
G1t38의 형체 형태 및 그의 제조 방법
|
|
CA3079407A1
(en)
|
2017-10-18 |
2019-04-25 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
EA038160B1
(ru)
*
|
2017-11-30 |
2021-07-15 |
Астразенека Аб |
Модуляторы рецептора эстрогена
|
|
CN109867659A
(zh)
*
|
2017-12-04 |
2019-06-11 |
江苏恒瑞医药股份有限公司 |
苯并哌啶类衍生物的制备方法
|
|
US10519152B2
(en)
*
|
2017-12-21 |
2019-12-31 |
Astrazeneca Ab |
Compounds and their use in treating cancer
|
|
JP7348663B2
(ja)
*
|
2018-02-23 |
2023-09-21 |
センター フォー インテリジェント リサーチ イン クリスタル エンジニアリング，エセ．エレ． |
ユビキノールの共結晶及びそれらを含む組成物
|
|
KR20200131816A
(ko)
|
2018-03-14 |
2020-11-24 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
캡시드 조립 조절제 투약 요법
|
|
CN112566666A
(zh)
|
2018-05-14 |
2021-03-26 |
努瓦申生物公司 |
靶向抗癌核激素受体的化合物
|
|
TW202016084A
(zh)
*
|
2018-05-30 |
2020-05-01 |
大陸商迪哲（江蘇）醫藥有限公司 |
選擇性雌激素受體下調劑和其用途
|
|
SI3810283T1
(sl)
|
2018-06-21 |
2023-10-30 |
F. Hoffmann-La Roche Ag |
Trdne oblike tartratne soli 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2H-pirido(3,4-b)indol-2-il)-2,2- difluoropropan-1-ola, postopek za njihovo pripravo in metode njihove uporabe pri zdravljenju raka
|
|
JP2021529757A
(ja)
|
2018-07-03 |
2021-11-04 |
ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ |
小胞体ストレス応答の活性剤
|
|
CN113453679B
(zh)
|
2018-12-20 |
2025-07-08 |
C4医药公司 |
靶向蛋白降解
|
|
AU2018454987B2
(en)
|
2018-12-24 |
2025-05-29 |
InventisBio Co., Ltd. |
Novel salts of selective estrogen receptor degraders
|
|
BR112021015618A2
(pt)
|
2019-02-22 |
2021-10-05 |
Janssen Sciences Ireland Unlimited Company |
Derivados de amida úteis no tratamento da infecção pelo hbv ou doenças induzidas pelo hbv
|
|
WO2020219742A1
(en)
|
2019-04-24 |
2020-10-29 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
TW202108576A
(zh)
|
2019-05-06 |
2021-03-01 |
愛爾蘭商健生科學愛爾蘭無限公司 |
用於治療ｈｂｖ感染或ｈｂｖ誘發的疾病之醯胺衍生物
|
|
AU2020274113A1
(en)
*
|
2019-05-14 |
2021-11-11 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
AU2020311337A1
(en)
|
2019-07-07 |
2022-01-20 |
Olema Pharmaceuticals, Inc. |
Regimens of estrogen receptor antagonists
|
|
KR20220044528A
(ko)
|
2019-08-06 |
2022-04-08 |
리커리엄 아이피 홀딩스, 엘엘씨 |
돌연변이체를 치료하기 위한 에스트로겐 수용체 조절제
|
|
CN114945570A
(zh)
*
|
2019-11-04 |
2022-08-26 |
里科瑞尔姆Ip控股有限责任公司 |
雌激素受体调节剂的盐和形式
|
|
TW202131930A
(zh)
|
2019-11-13 |
2021-09-01 |
美商諾維雪碧歐公司 |
抗癌核荷爾蒙受體標靶化合物
|
|
CA3154073A1
(en)
|
2019-12-20 |
2021-06-24 |
Christopher G. Nasveschuk |
Isoindolinone and indazole compounds for the degradation of egfr
|
|
CN114746424B
(zh)
|
2020-01-10 |
2023-06-16 |
江苏恒瑞医药股份有限公司 |
三环四氢异喹啉类衍生物、其制备方法及其在医药上的应用
|
|
EP4114392A4
(en)
|
2020-03-05 |
2024-04-10 |
C4 Therapeutics, Inc. |
Compounds for targeted degradation of brd9
|
|
JP7708772B2
(ja)
|
2020-03-06 |
2025-07-15 |
オレマ ファーマシューティカルズ インク． |
エストロゲン受容体関連疾患の治療方法
|
|
CA3179907A1
(en)
|
2020-04-24 |
2021-10-28 |
Astrazeneca Ab |
Dosage regimen for the treatment of cancer
|
|
BR112022021089A2
(pt)
|
2020-04-24 |
2022-12-06 |
Astrazeneca Ab |
Formulações farmacêuticas
|
|
WO2021253380A1
(en)
*
|
2020-06-19 |
2021-12-23 |
InventisBio Co., Ltd. |
Oral formulations and uses thereof
|
|
CN116490186B
(zh)
|
2020-08-05 |
2025-10-31 |
C4医药公司 |
用于ret的靶向降解的化合物
|
|
MX2023001572A
(es)
*
|
2020-08-05 |
2023-05-08 |
Aizant Drug Res Solutions Private Limited |
Formas farmaceuticas sólidas de palbociclib.
|
|
WO2022109395A2
(en)
|
2020-11-23 |
2022-05-27 |
Sanofi |
Panel of er regulated genes for use in monitoring endocrine therapy in breast cancer
|
|
JP2024502270A
(ja)
|
2020-12-23 |
2024-01-18 |
リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー |
エストロゲン受容体調節薬
|
|
IL306010A
(en)
|
2021-03-23 |
2023-11-01 |
Nuvation Bio Inc |
Anticancer compounds against the nuclear hormone receptor
|
|
CA3218577A1
(en)
|
2021-05-03 |
2022-11-10 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
CA3174245A1
(en)
|
2021-06-08 |
2022-12-15 |
Christopher G. Nasveschuk |
Therapeutics for the degradation of mutant braf
|
|
IL309986A
(en)
*
|
2021-07-08 |
2024-03-01 |
Olema Pharmaceuticals Inc |
Methods of treating estrogen receptor-associated diseases
|
|
CN117642405A
(zh)
|
2021-07-09 |
2024-03-01 |
江苏恒瑞医药股份有限公司 |
一种三环四氢异喹啉类衍生物的盐型
|
|
WO2023221123A1
(en)
*
|
2022-05-20 |
2023-11-23 |
Olema Pharmaceuticals, Inc. |
Crystalline forms of an estrogen receptor antagonist
|
|
EP4565585A1
(en)
|
2022-08-03 |
2025-06-11 |
Bristol-Myers Squibb Company |
Compounds for modulating ret protein
|
|
KR20250116017A
(ko)
|
2022-11-04 |
2025-07-31 |
브리스톨-마이어스 스큅 컴퍼니 |
Ret-ldd 단백질 억제제
|
|
JP2025540907A
(ja)
|
2022-11-04 |
2025-12-17 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｒｅｔ－ｌｄｄタンパク質分解誘導剤
|
|
KR20240170460A
(ko)
*
|
2023-05-25 |
2024-12-03 |
주식회사 삼양홀딩스 |
팔보시클립의 경구용 조성물
|
|
WO2025006753A2
(en)
|
2023-06-30 |
2025-01-02 |
Merck Patent Gmbh |
Heterobifunctional compounds for the degradation of kras protein
|